Menu
← Oncology Approval Tracker
FDA DECISION ·
Brukinsa + obinutuzumab
zanubrutinib with obinutuzumab · BeiGene
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines; use with obinutuzumab.
LAMPGEN ANALYSIS
Why it matters
The combination adds a BTK inhibitor and anti-CD20 option for previously treated follicular lymphoma.
What research teams should watch
Plan infusion premedication, infection screening and reconciliation of bleeding-risk medications alongside oral treatment.
PRIMARY RECORDS